Boston Scientific
BSX
41.58
-0.61
-1.45%
Boston Scientific
US · BSX
#364 by market cap
Listed 1970
41.58
-0.61
-1.45%
Live - 5344 symbols - heartbeat 427s ago
· 2026-10-08 07:37
Pre-market
41.50
-0.19%
After-hours
41.70
+0.29%
Overnight
41.64
+0.14%
- Market cap
- 60.26B
- P/E (TTM)i
- 16.83
- P/Bi
- 2.42
- EPSi
- 1.94
- Div yieldi
- 0.00%
- 52W posi
- 0%
Reader sentiment
Are you bullish or bearish on BSX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 13 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 93.97% -0.16pp
- Institutions
- 1,865 -13
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund72.92%
Hedge Fund8.57%
Public Company3.52%
Government Pension Fund3.03%
Private Company2.91%
Sovereign Wealth Fund1.54%
VC/PE Fund0.56%
Corporate Pension Plan0.35%
Insurance Company0.21%
Other6.38%
Top holders as of 2026-06-30
BlackRock
8.95% · 129.68M sh
Vanguard Capital Management, LLC
7.28% · 105.43M sh
State Street Global Advisors
4.84% · 70.11M sh
PRIMECAP Management Company
3.49% · 50.52M sh
FMR
2.73% · 39.53M sh
Other
72.73%
Geode Capital Management, LLC
2.31% · 33.44M sh
Capital Research
2.17% · 31.49M sh
Vanguard Portfolio Management, LLC
2.06% · 29.79M sh
UBS Asset Management
2.03% · 29.44M sh
D. E. Shaw & Co., L.P.
1.76% · 25.46M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 11 sells
| Name | Role | Stake |
|---|---|---|
| Michael Mahoney | Chairperson & CEO | 0.11% |
| Joseph Fitzgerald | Executive VP & Group President of Cardiology | 0.02% |
| Daniel Brennan | Chief Financial Officer | 0.01% |
| Arthur Crosswell Butcher | Executive VP and Group President of MedSurg & Asia Pacific | 0.01% |
| Jeffrey Mirviss | Executive VP & President of Peripheral Interventions | 0.00% |
| Charles Dockendorff | Independent Director | 0.00% |
| John Sununu | Independent Director | 0.00% |
| Vance Brown | Senior Vice President | 0.00% |
| Jonathan Monson | Senior VP, Global Controller & Chief Accounting Officer | 0.00% |
| David Wichmann | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Padraig O'Connor | -- | Derivative Exercise and Sale | -567 | $48.37 |
| 2026-09-01 | Padraig O'Connor | -- | Derivative Exercise and Retained | +604 | -- |
| 2026-08-24 | Susan Morano | Director | Open Market Acquisition | +2,040 | $49.22 |
| 2026-08-10 | Emily Woodworth | Senior VP, Global Controller & Chief Accounting Officer | Acquisition Under Employee Benef | +2,930 | $51.19 |
| 2026-08-09 | Jonathan Monson | Senior VP, Global Controller & Chief Accounting Officer | Acquisition Under Employee Benef | +9,908 | $50.46 |
| 2026-08-04 | David Habiger | Director | Open Market Acquisition | +2,100 | $47.59 |
| 2026-08-03 | David Habiger | Director | Open Market Acquisition | +1,182 | $48.07–48.59 |
| 2026-08-02 | Michael Mahoney | Chairperson & CEO | Open Market Acquisition | +186,240 | $48.33 |
| 2026-08-02 | Michael Mahoney | Chairperson & CEO | Acquisition Under Employee Benef | +22,119 | $48.43 |
| 2026-07-30 | Edward Ludwig | Lead Independent Director | Open Market Acquisition | +5,000 | $45.48 |
| 2026-07-30 | Joseph Fitzgerald | Executive VP & Group President of Cardiology | Acquisition Under Employee Benef | +64,198 | $46.73 |
| 2026-06-30 | Jonathan Monson | Senior VP, Global Controller & Chief Accounting Officer | Derivative Exercise and Sale | -1,010 | $43.06 |
| 2026-06-30 | Jonathan Monson | Senior VP, Global Controller & Chief Accounting Officer | Derivative Exercise and Retained | +1,077 | -- |
| 2026-05-27 | Michael Mahoney | Chairperson & CEO | Other Disposition | -386,755 | -- |
| 2026-05-19 | Edward Ludwig | Lead Independent Director | Open Market Acquisition | +3,580 | $56.68 |
| 2026-05-19 | Cheryl Pegus | Director | Open Market Acquisition | +1,770 | $56.49 |
| 2026-05-19 | David Habiger | Director | Open Market Acquisition | +4,450 | $55.92–56.95 |
| 2026-05-06 | Edward Ludwig | Lead Independent Director | Other Acquisition | +3,800 | -- |
| 2026-05-06 | Ellen Zane | Independent Director | Other Acquisition | +3,800 | -- |
| 2026-05-06 | David Wichmann | Independent Director | Other Acquisition | +3,800 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:37:45 · For reference only, not investment advice and not tailored to your situation.